Introduction
============

There has been an increasing incidence of tubulointerstitial nephritis (TIN).[@b1-tcrm-14-1599],[@b2-tcrm-14-1599] TIN is characterized by histologic interstitial abnormalities that reflect infiltration by various inflammatory cells, including lymphocytes, plasma cells, and macrophages,[@b3-tcrm-14-1599] and is often accompanied by tubulitis. The common clinical presentations are rash, fever, eosinophilia, and elevated immunoglobulin E (IgE) levels, but patients often present with nonspecific symptoms, which can lead to delayed diagnosis and treatment of the disease, resulting in renal dysfunction.[@b4-tcrm-14-1599]

The causes of TIN vary and include drug reactions,[@b5-tcrm-14-1599] infections,[@b6-tcrm-14-1599] and autoimmune diseases[@b7-tcrm-14-1599] such as Sjögren syndrome or IgG4-related disease. Recently, drug-induced TIN has accounted for more than two-thirds of the cases.[@b8-tcrm-14-1599] A large number of drugs have been associated with TIN, and any drug can theoretically induce an episode of acute TIN. In most patients, renal function improves after discontinuation of the drug, but the renal function does not recover fully in some cases.[@b9-tcrm-14-1599] TIN often occurs without any abnormal urinalysis findings, which makes it difficult to identify at an early stage.[@b10-tcrm-14-1599] Therefore, it is important to know which drugs more often cause TIN in clinical settings. However, few studies have performed surveillance of the rank ordering of the drugs associated with TIN. The objective of this study was to conduct a comprehensive nationwide overview of drug-induced TIN using a spontaneously reported adverse drug reactions (ADRs) database in Japan.

Materials and methods
=====================

The present study used data from the public release of Pharmaceuticals and Medical Devices Agency's Japanese Adverse Drug Event Report (JADER) database, which contains information on the ADRs and patients in Japan since April 1, 2004. We used data from the JADER to which adverse event reports were submitted between April 2004 and January 2017. The data structure of JADER consists of 4 data sets: patient demographic information (DEMO), drug information (DRUG), adverse reactions (REAC), and medical history. In REAC table, the Medical Dictionary for Regulatory Activities (MedDRA) is used to codify the adverse reactions, which are indicated as "Preferred Term (PT)".

After we removed duplicated data from each table,[@b11-tcrm-14-1599] the DEMO table was then linked to the REAC and DRUG tables using the ID number. In each case, the contribution of the medication to adverse reactions was classified into three categories: "suspected medicine," "concomitant medicine," and "interaction." A "suspected medicine" is defined as a pharmaceutical product with which an adverse reaction is suspected to be associated. When the reporter suspects an interaction, he/she reports it as an "interaction." A "concomitant medicine" is defined as another pharmaceutical product used at the time of the adverse reaction.

We only extracted cases that were classified as "suspected medicine" and analyzed the reports of suspected drugs and ADRs, which we selected as "TIN" in the PT coded in MedDRA (version 20.1). We compiled a cross-tabulation table based on two classifications: the presence or absence of TIN and the presence or absence of the suspected medicine. Therefore, we calculated the reporting odds ratio (ROR). The ROR is rate of reporting a specific adverse reaction caused by a particular drug divided by the rate of the same adverse reactions caused by all other drugs present in the database. In addition, the ROR was frequently used with the spontaneous reporting database as an index of the relative risk of drug-associated adverse reactions. A signal was considered to be present when the lower limit of the 95% CI of the ROR was \>1.

In this database, age, height, and weight information are indicated in the form of age in decades, height in centimeter-denominated ranges, and weight in kilogram-denominated ranges. Because these data are not continuous variables, we could not conduct multiple analyses using them. All analyses were performed with JMP Pro 12 (SAS Institute Inc., Cary, NC, USA).

Results
=======

In total, 5,195,890 reports were obtained after the combination of three tables, DRUG (2,850,470 reports), REAC (709,826 reports), and DEMO (449,558 patients), with the ID number. Of those, we extracted suspected drugs causing all adverse reactions (1,984,122 reports) and obtained 3,088 reports of suspected drugs and TIN (corresponding to 0.16% of all records in the JADER). The annual numbers of reports for 2004--2016 are shown in [Table 1](#t1-tcrm-14-1599){ref-type="table"}. Of note, the number of deaths associated with TIN was extremely low, but the rate of nonrecovery from drug-induced TIN was high. As shown in [Table 2](#t2-tcrm-14-1599){ref-type="table"}, approximately 60% of the patients were men. According to the age distribution of the study population, TIN occurred frequently in those in their 60s (21.6%). The most frequent duration of treatment until TIN was within 1 month (16.8%) (1 week, 12.0%; 2 weeks, 3.6%; 4 weeks, 1.2%), and the second most frequent was 12 weeks (13.7%). The TIN outcomes were distributed as follows: 0.3% of the patients died, 65.8% had recovered or were recovering, 12.1% had not recovered, 5.6% had after-effects, and the outcome was unknown in the remaining 16.2%.

In our analysis, 427 different drugs were "suspected" in cases of TIN. Of these, the drugs ranked in order of the frequency of a reported association with TIN were examined. The first 65 medications gave a positive signal, that is, the lower confidence limit of the ROR was \>1 ([Table 3](#t3-tcrm-14-1599){ref-type="table"}). The most frequently reported drug was gliclazide (ROR, 30.5; 95% CI, 17.4--53.2), followed by tosufloxacin tosilate hydrate (ROR, 29.5; 95% CI, 21.3--41.0), piperacillin--tazobactam (ROR, 24.3; 95% CI, 19.4--30.5), cefteram pivoxil (ROR, 23.5; 95% CI, 12.5--44.2), mefenamic acid (ROR, 22.5; 95% CI, 13.4--37.7), cefotaxime sodium (ROR, 21.5; 95% CI, 11.5--40.5), and mesalazine (ROR, 20.1; 95% CI, 16.1--25.0).

Discussion
==========

TIN is a frequent and important clinical problem that can be induced by a variety of medications. In our results, of the 1,984,122 reports of ADRs recorded in JADER during the study period, 3,088 (0.16%) corresponded to TIN. Our results also reveal that the duration of the exposure to drugs until the onset of TIN was most often within 12 weeks. Furthermore, we found that most TIN survivors achieved recovery or remission after the index TIN episode. However, the recovery from TIN was worse compared to all other ADRs across the 12-year time span.

The clinical presentation of TIN is highly variable. The only consistent clinical manifestation is acute or subacute kidney injury, often resulting in chronic kidney disease (CKD).[@b12-tcrm-14-1599],[@b13-tcrm-14-1599] The most common etiology of TIN is drug-induced disease, which is thought to underlie approximately 70% of cases.[@b8-tcrm-14-1599] Antibiotics,[@b14-tcrm-14-1599] antiviral medications,[@b15-tcrm-14-1599] anticonvulsants,[@b16-tcrm-14-1599] analgesics,[@b17-tcrm-14-1599] and gastrointestinal medications[@b18-tcrm-14-1599] are associated with TIN. Historically, the prevalence of TIN was reported to be higher in patients over 60 years than in those under 60 years.[@b19-tcrm-14-1599] A Spanish biopsy registry study from 1994 to 2009 showed that the prevalence of TIN had markedly increased in elderly patients.[@b1-tcrm-14-1599] Consistent with these reports, our results reveal that many of the patients with TIN were elderly (most frequently in their 60s). It has been postulated that the reason may be because of a reduced kidney function, which results in the accumulation of drugs and/or their metabolites, resulting in an increased risk of developing serious side effects. Another possibility is that the elderly have concomitant diseases, such as cardiovascular disease, CKD, diabetes, or heart failure; therefore, they have higher rates of diagnostic procedures and take several nephrotoxic agents.[@b20-tcrm-14-1599]

We found the duration of exposure to drugs until TIN onset was most often within 12 weeks. This finding is line with a single-center retrospective analysis showing that 8 out of 14 cases with presumed drug-related TIN could be attributed to proton pump inhibitors (PPIs) and that the duration of PPI treatment before presentation was between 2 weeks and 9 months.[@b21-tcrm-14-1599]

Of note, our results revealed that gliclazide, a sulphonylurea-class molecule used to control glycemic levels in patients with noninsulin-dependent diabetes mellitus, exhibited the highest ROR of TIN. So far, there have been few studies on the renal toxicity of gliclazide. In addition, the Japanese medical package insert of gliclazide (Glimicron^®^; Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan) state that the frequency of ADRs affecting the kidney is very low (increases in blood urea nitrogen and serum creatinine are under 0.1% and unknown, respectively). To the best of our knowledge, this is the first study to report the association of gliclazide with TIN.

In our results, antibiotics (such as tosufloxacin tosilate hydrate, piperacillin--tazobactam, cefteram pivoxil, and cefotaxime sodium), nonsteroidal anti-inflammatory drugs (NSAIDs) (such as mefenamic acid, loxoprofen sodium hydrate, and ketoprofen), and drugs against methicillin-resistant *Staphylococcus aureus* (MRSA) (such as vancomycin and rifampicin) exhibited high RORs. This observation is in accordance with previous reports showing that the main causes of TIN were antibiotics, NSAIDs, and anti-MRSA antibiotics.[@b1-tcrm-14-1599],[@b9-tcrm-14-1599],[@b22-tcrm-14-1599]--[@b24-tcrm-14-1599] Recently, PPI-induced TIN has been increasingly reported. Biopsy-proven TIN from 1993 to 2011 showed that drug-induced TIN was due to antibiotics in 49% of the cases, PPIs in 14%, and NSAIDs in 11%.[@b10-tcrm-14-1599] In the present study, we also found that the ROR of omeprazole was significantly higher.

Importantly, we found that mesalazine-induced TIN was frequently reported. There have been few reports on the outcome of mesalazine-induced TIN. A case report showed that the withdrawal of mesalazine and initiation of intravenous methylprednisolone led to the recovery of a patient's renal function.[@b25-tcrm-14-1599] However, our results revealed that there were high frequencies of nonrecovering mesalazine-induced TIN.

Limitations
===========

The JADER database is considered to be a valuable tool;[@b26-tcrm-14-1599] however, several limitations inherent to spontaneous reporting are included. First, the JADER database has various biases, such as the lack of a denominator that indicates the total number of patients who received the drugs of interest, as well as missing data and confounding factors. Second, the ROR does not provide a robust indication of the signal strength. In spontaneous reporting systems such as JADER, control populations are not included, so the ROR is different from the "odds ratio" that is commonly used in epidemiological studies. In real terms, the ROR indicates an increased risk of adverse event reporting, and not the risk of adverse reactions. Third, the date of outcome is not included in this database. Therefore, it is difficult to assess the average duration between stopping the offending drug and recovery of renal function. Finally, the present method did not provide us with detailed information on the patients' clinical status. Clinically unstable patients are more likely to develop TIN and to be taking several concomitant drugs than stable patients; this situation may be a confounding factor when estimating the occurrence of TIN.

Conclusion
==========

The suspected drugs associated with TIN determined using a nationwide pharmacovigilance database strongly suggest that physicians should be alerted to take precautions against drugs inducing TIN, select appropriate therapeutic medicine, and potentially avoid TIN.
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###### 

Numbers of all ADRs and TIN from 2004 to 2016

                             Year                                                                                                                    
  -------------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  All ADRs                                                                                                                                           
   Total number of reports   86,287    109,049   111,224   120,135   133,760   127,469   157,672   184,380   212,583   160,534   194,853   211,587   174,589
   Death due to all          6,841     8,296     8,081     9,128     10,247    10,133    10,603    11,397    10,122    10,130    13,928    13,557    11,678
   ADRs                      (7.9%)    (7.6%)    (7.3%)    (7.6%)    (7.7%)    (7.9%)    (6.7%)    (6.2%)    (4.8%)    (6.3%)    (7.1%)    (6.4%)    (6.7%)
   Nonrecovery from          8,178     10,234    10,534    10,846    12,773    12,425    16,549    18,647    24,031    15,025    20,838    22,709    15,183
   ADRs                      (9.5%)    (9.4%)    (9.5%)    (9.0%)    (9.5%)    (9.7%)    (10.5%)   (10.1%)   (11.3%)   (9.4%)    (10.7%)   (10.7%)   (8.7%)
  TIN                                                                                                                                                
   Total number of reports   159       174       122       150       266       140       143       214       351       241       395       428       305
   Death due to              0         2         0         0         1         0         0         2         0         0         1         4         0
   drug-induced TIN          (0%)      (1.2%)    (0%)      (0%)      (0.4%)    (0%)      (0%)      (0.9%)    (0%)      (0%)      (0.3%)    (0.9%)    (0%)
   Nonrecovery from          31        19        12        4         67        35        10        37        30        18        46        36        28
   drug-induced TIN          (19.5%)   (10.9%)   (9.8%)    (2.7%)    (25.2%)   (25.0%)   (7.0%)    (17.3%)   (8.5%)    (7.5%)    (11.6%)   (8.4%)    (9.2%)

**Abbreviations:** ADR, adverse drug reaction; TIN, tubulointerstitial nephritis.

###### 

Characteristics of the patients with drug-induced TIN

  Variables                             N       Percent
  ------------------------------------- ------- ---------
  Sex                                           
   Men                                  1,766   57.2
   Women                                1,301   42.1
   Unknown                              21      0.7
  Age (years)                                   
   Under 10                             137     4.5
   10s                                  270     8.7
   20s                                  153     5.0
   30s                                  239     7.7
   40s                                  271     8.8
   50s                                  415     13.4
   60s                                  668     21.6
   70s                                  510     16.5
   80s                                  335     10.9
   90s                                  37      1.2
   Unknown                              53      1.7
  Period for treatment at the episode           
   1 week                               371     12.0
   2 weeks                              110     3.6
   4 weeks                              36      1.2
   12 weeks                             422     13.7
   24 weeks                             63      2.0
   1 year                               212     6.9
   After 1 year                         211     6.8
   Unknown                              1,663   53.8

**Abbreviation:** TIN, tubulointerstitial nephritis.

###### 

Most frequently reported drugs that induce TIN

  Suspected drug                            Cases (n)   ROR    95% CI
  ----------------------------------------- ----------- ------ ------------
  Gliclazide                                13          30.5   17.4--53.2
  Tosufloxacin tosilate hydrate             38          29.5   21.3--41.0
  Piperacillin--tazobactam                  80          24.3   19.4--30.5
  Cefteram pivoxil                          10          23.5   12.5--44.2
  Mefenamic acid                            15          22.5   13.4--37.7
  Cefotaxime sodium                         10          21.5   11.5--40.5
  Mesalazine                                85          20.1   16.1--25.0
  Piperacillin sodium                       97          19.6   16.0--24.1
  Polaprezinc                               10          19.3   10.3--36.2
  Teneligliptin hydrobromide hydrate        11          17.8   9.8--32.4
  Benidipine hydrochloride                  14          17.4   10.2--29.6
  Loxoprofen sodium hydrate                 205         15.8   13.7--18.2
  Ketoprofen                                11          15.5   8.5--28.3
  Loratadine                                10          14.4   7.7--27.0
  Cefdinir                                  21          14.1   9.2--21.8
  Tretinoin                                 12          13.6   7.7--24.2
  Cefditoren pivoxil                        23          12.8   8.5--19.4
  Ibuprofen                                 14          12.7   7.5--21.5
  Ursodeoxycholic acid                      17          11.6   7.2--18.8
  Pyrazinamide                              17          11.6   7.2--18.8
  Acetaminophen                             116         11.5   9.6--13.9
  Limaprost alfadex                         13          11.5   6.7--20.0
  Atazanavir sulfate                        11          10.3   5.7--18.8
  Omeprazole                                39          10.2   7.4--14.1
  Rebamipide                                43          10.2   7.5--13.8
  Enalapril maleate                         20          10.2   6.5--15.9
  Rifampicin                                35          9.6    6.9--13.5
  Cefcapene pivoxil hydrochloride hydrate   33          9.4    6.6--13.2
  Montelukast sodium                        10          8.3    4.4--15.5
  Abacavir sulfate                          14          7.2    4.2--12.1
  Eldecalcitol                              14          7.1    4.2--12.0
  Vancomycin hydrochloride                  40          7.1    5.2--9.7
  Ethambutol hydrochloride                  20          6.9    4.4--10.7
  Moxifloxacin hydrochloride                10          6.7    3.6--12.6
  Levofloxacin hydrate                      58          6.7    5.1--8.7
  Diclofenac sodium                         66          6.6    5.2--8.5
  Famotidine                                50          6.2    4.7--8.2
  Isoniazid                                 21          5.5    3.6--8.5
  Candesartan cilexetil                     24          5.2    3.5--7.7
  Minocycline hydrochloride                 18          5.1    3.2--8.1
  Risedronate sodium hydrate                13          5.1    2.9--8.8
  Clarithromycin                            40          5.0    3.6--6.8
  Ceftriaxone sodium hydrate                27          4.9    3.4--7.2
  Cefazolin sodium                          15          4.6    2.8--7.7
  Lansoprazole                              45          4.5    3.3--6.0
  Allopurinol                               42          4.4    3.2--5.9
  Rosuvastatin calcium                      14          4.2    2.5--7.2
  Sodium rabeprazole                        13          4.1    2.4--7.2
  Ampicillin--sulbactam                     11          4.1    2.3--7.5
  Meropenem hydrate                         22          4.1    2.7--6.3
  Carbocisteine                             12          4.0    2.3--7.1
  Amoxicillin hydrate                       25          3.9    2.7--5.9
  Adefovir pivoxil                          11          3.9    2.2--7.1
  Garenoxacin mesilate hydrate              15          3.8    2.3--6.3
  Atorvastatin calcium hydrate              18          3.1    1.9--4.9
  Lamivudine                                18          2.9    1.8--4.7
  Glimepiride                               15          2.9    1.7--4.8
  Amlodipine besilate                       25          2.9    1.9--4.3
  Sodium valproate                          30          2.6    1.8--3.8
  Aspirin                                   32          2.3    1.7--3.3
  Trimethoprim-Sulfamethoxazole             17          2.2    1.3--3.5
  Celecoxib                                 12          1.9    1.1--3.3
  Valaciclovir hydrochloride                17          1.7    1.1--2.7
  Pregabalin                                27          1.7    1.2--2.5
  Carbamazepine                             29          1.5    1.1--2.2

**Abbreviations:** ROR, reporting odds ratio; TIN, tubulointerstitial nephritis.
